Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant annexin A5 - Annexin Pharmaceuticals

Next Previous
X
Search
Drug Profile

Recombinant annexin A5 - Annexin Pharmaceuticals

Alternative Names: ANXV

Latest Information Update: 19 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Annexin Pharmaceuticals
  • Developer Annexin Pharmaceuticals; Maastricht University Medical Center
  • Class Anti-inflammatories; Anti-ischaemics; Anticoagulants; Antithrombotics; Antivirals; Biological peptides; Calcium binding proteins; Cardiovascular therapies; Eye disorder therapies; Recombinant fusion proteins; Recombinant proteins
  • Mechanism of Action Phosphatidylserine receptor modulators; Phospholipase A2 inhibitors; Urokinase-type plasminogen activator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cardiovascular disorders

Highest Development Phases

  • Phase II COVID-19 pneumonia; Retinal vein occlusion
  • Preclinical Cancer
  • Research Viral infections
  • No development reported Cardiovascular disorders

Most Recent Events

  • 31 May 2024 Pharmacodynamics data from a preclinical trial in Cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 28 Jan 2024 No recent reports of development identified for phase-I development in Cardiovascular-disorders(In volunteers) in Netherlands (IV, Infusion)
  • 29 Sep 2023 Preclinical trials in Cancer in Sweden (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top